İn Vitro Hepatik Oksidatif Hasarda Karvakrolün Etkinliğinin Araştırılması.

Non-alcoholic fatty liver disease (NAFLD); is a common disease characterized by accumulation of fat in the liver, especially triglycerides. Research in the treatment of the disease has focused on antioxidant molecules derived from natural sources. In this context, hepatoprotective effect of carvacrol has been tried to be demonstrated by in vitro experiments. Human hepatocyte cell line (HepG2, ATCCHB-8065) was used in the study. Experimental groups were designed as control (K), palmitate added group (P), carvacrol added group (C) and palmitate and carvacrol added group (+ C). Different concentrations of palmitate (150, 300 and 450 µM) and carvacrol (1, 5, 10 and 50 µM) were applied to the cells for 24 hours and effective concentration determinations were determined by MTT viability test. Intracellular glutathione and nitrite levels were analyzed spectrophotometrically from lysates obtained from cells. Besides, aldose reductase levels (AR) in these samples were investigated by ELISA method. According to the viability data obtained from the study, it was found that 300 µM concentration of palmitate caused 45% cell losses compared to the control, and 5 µM concentration of carvacrol prevented 41% of these cell losses. In this study, palmitate and carvacrol did not produce a significant change in GSH levels but it significantly reduced NO levels. In addition, palmitate increased intracellular AR protein level, while carvacrol inhibited this increase by 1.7%. According to all these data, it was concluded that carvacrol can be considered as a potential active agent in fatty liver diseases such as nonalcoholic fatty liver disease. [ABSTRACT FROM AUTHOR]